"11:15 Agenus? Synthetic Neoantigen Vaccine Platforms, Including Novel Phosphopeptide Tumor Targets Levey_DanielDaniel Levey, PhD, Senior Director Vaccine Research, R&D, Agenus, Inc.
Agenus? vaccine platform of synthetic neoantigens complexed to recombinant heat shock protein 70 (HSC70) and administered along with QS-21 Stimulon® adjuvant elicits an antigen-specific immune response in both mice and humans. Leveraging our in silico Agenus Immunogenic Mutation (AIM?) workflow, we are able to generate an optimal immunogenic vaccine blueprint for our AutoSynVax? vaccines, which are uniquely designed and manufactured for each patient based on NGS profiling of their tumor. Our PhosphoSynVax? vaccine is an off-the-shelf vaccine targeting a novel class of tumor neoantigens."